HE4 for Earlier Detection of Ovarian Cancer
Ovarian Cancer affects 7000 women every year in the UK.
HE4 shows a higher specificity to ovarian cancer over that of
CA12-5 alone. The combination of HE4 and CA12-5 together improves
diagnostic sensitivity compared to either marker alone in the
detection of ovarian cancer in women with pelvic masses. In
addition, 20% of women with ovarian cancer will not have an
elevated CA12-5. False positive CA12-5 levels are noted in
approximately 25% of women. HE4 together with its partnered
CA 12-5 discriminates better between ovarian cancer and benign
conditions. It has also been observed that HE4 serum levels
become normal following treatment, suggesting that HE4 could be
used for the follow up of ovarian cancer.